Jacobs Levy Equity Management Inc. Has $705,000 Position in Aclaris Therapeutics, Inc. $ACRS

Jacobs Levy Equity Management Inc. lowered its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 20.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 460,842 shares of the biotechnology company’s stock after selling 115,200 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.43% of Aclaris Therapeutics worth $705,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Graham Capital Management L.P. bought a new stake in Aclaris Therapeutics in the fourth quarter valued at about $35,000. Alpine Global Management LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $38,000. Alps Advisors Inc. boosted its position in shares of Aclaris Therapeutics by 36.4% during the first quarter. Alps Advisors Inc. now owns 78,782 shares of the biotechnology company’s stock worth $121,000 after buying an additional 21,022 shares during the period. Velan Capital Investment Management LP acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $67,000. Finally, Jefferies Financial Group Inc. boosted its position in Aclaris Therapeutics by 253.9% during the fourth quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 29,200 shares during the last quarter. Institutional investors own 98.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ACRS. Piper Sandler assumed coverage on Aclaris Therapeutics in a research report on Thursday, July 10th. They set an “overweight” rating and a $6.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday, June 25th. Finally, Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Aclaris Therapeutics in a research note on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $8.71.

Aclaris Therapeutics Stock Performance

Shares of ACRS opened at $1.95 on Friday. The stock has a 50 day moving average price of $1.73 and a two-hundred day moving average price of $1.54. The firm has a market capitalization of $211.24 million, a P/E ratio of -1.42 and a beta of 0.27. Aclaris Therapeutics, Inc. has a 52 week low of $1.05 and a 52 week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.The firm had revenue of $1.78 million for the quarter, compared to the consensus estimate of $1.34 million. On average, equities analysts forecast that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.